Sign in
CompletedNo phase

Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial

Key facts

Who runs it
Yanqing Li
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
372 people enrolled
Started
20 Sept 2025
Ended
30 Jun 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • 14-day vonoprazan-amoxicillin dual therapy
  • 14-day vonoprazan-amoxicillin-levofloxacin-bismuth quadruple therapy
  • 14-day vonoprazan-amoxicillin-clarithromycin-bismuth quadruple therapy
Record updated
23 October 2026

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Aged 18-70 years, male or female
  • Patients with H. pylori infection (positive 13C-urea breath test, together with at least one positive result from the following three tests: (a) stool H. pylori antigen test; (b) rapid urease test; (c) histopathological examination of gastric mucosal biopsy tissue)
  • No prior Helicobacter pylori eradication therapy

Who cannot take part

  • Presence of other risk-increasing behaviours such as alcohol abuse or illicit drug use
  • Severe underlying conditions, such as hepatic insufficiency, renal insufficiency, malignant tumours
  • Active gastrointestinal bleeding
  • History of upper gastrointestinal surgery
  • History of drug hypersensitivity
  • Use of bismuth compounds or antibiotics within the past 4 weeks, or acid-suppressing agents within the past 2 weeks
  • Pregnant or lactating women
  • Individuals unable or unwilling to provide informed consent

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is a multicentre, non-inferiority randomized controlled trial to compare the efficacy and safety of 14-day vonoprazan-based dual therapy with versus quadruple therapy for the eradication of Helicobacter pylori. The primary outcome is eradication rate, and the secondary outcome includes the incidence of adverse events and compliance.

The 3 groups in the trial

  • 14-day vonoprazan-amoxicillin dual therapyTreatment being tested
  • 14-day vonoprazan-amoxicillin-levofloxacin-bismuth quadruple therapyExisting treatment, for comparison
  • 14-day vonoprazan-amoxicillin-clarithromycin-bismuth quadruple therapyExisting treatment, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
23 October 2026